Dyhor-19: Diagnosis of Endocrine Dysfunctions in Covid-19
Study Details
Study Description
Brief Summary
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course.
Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described.
Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease.
In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Plasma aldosterone levels [1 day (at inclusion)]
Plasma aldosterone levels
- Plasma renin levels [1 day (at inclusion)]
Plasma renin levels
Secondary Outcome Measures
- covid-19 infection severity [1 day (at inclusion)]
covid-19 infection severity : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
- Maximum severity of Covid-19 infection [1 day (at inclusion)]
Maximum severity of Covid-19 infection using a seven-category ordinal scale at at the end of hospitalization : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
- Plasma aldosterone level [1 day (at the end of hospitalization)]
Plasma aldosterone level
- Plasma ACTH level [1 day (at the end of hospitalization)]
Plasma ACTH level
- Plasma cortisol level [1 day (at inclusion)]
Plasma cortisol level
- Plasma cortisol level [1 day (at the end of hospitalization)]
Plasma cortisol level
- Plasma T3l level [1 day (at the end of hospitalization)]
Plasma T3l level
- Plasma T3l level [1 day (at inclusion)]
Plasma T3l level
- Plasma ACTH level [1 day (at inclusion)]
Plasma ACTH level
- Plasma LH level [1 day (at inclusion)]
Plasma LH level
- Plasma LH level [1 day (at the end of hospitalization)]
Plasma LH level
- Plasma DHEA level [1 day (at the end of hospitalization)]
Plasma DHEA level
- Plasma DHEA level [1 day (at inclusion)]
Plasma DHEA level
- Plasma estradiol (female) or testosterone (male) level [1 day (at the end of hospitalization)]
Plasma estradiol (female) or testosterone (male) level
- Plasma estradiol (female) or testosterone (male) level [1 day (at inclusion)]
Plasma estradiol (female) or testosterone (male) level
- Plasma FSH level [1 day (at the end of hospitalization)]
Plasma FSH level
- Plasma FSH level [1 day (at inclusion)]
Plasma FSH level
- type of treatments [1 day]
type of treatments
- Clinical characteristics [1 day]
Clinical characteristics extracted from electronic medical
- radiological characteristics [1 day]
radiological characteristics : quantification of the percentage of lesional damage to the pulmonary parenchyma
Eligibility Criteria
Criteria
Inclusion criteria:
- Patients with Covid-19 diagnosis and hospitalized in our clinic
Exclusion criteria:
- Minor patient
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Uhmontpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
Investigators
- Study Director: Philippe GUILPAIN, MD, PhD, University Hospital, Montpellier
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RECHMPL20_0205